+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Anti Tumour Necrosis Factor"

Tumor Necrosis Factor Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Tumor Necrosis Factor Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 177 Pages
  • Global
From
Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 62 Pages
  • Global
From
CD40 Ligand Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

CD40 Ligand Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 49 Pages
  • Global
From
Cells Expressing CD40 Ligand Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Cells Expressing CD40 Ligand Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 40 Pages
  • Global
From
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2019 - Product Thumbnail Image

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2019

  • Drug Pipelines
  • April 2019
  • 85 Pages
  • Global
From
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Pipeline Review, H2 2018 - Product Thumbnail Image

Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Pipeline Review, H2 2018

  • Drug Pipelines
  • November 2018
  • 39 Pages
  • Global
From
2025 Global Forecast for Anti-Tnf-A Monoclonal Antibody Market (2026-2031 Outlook)-High Tech Outlook Report - Product Thumbnail Image

2025 Global Forecast for Anti-Tnf-A Monoclonal Antibody Market (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • January 2025
  • 132 Pages
  • Global
From
Psoriasis Therapeutics Market By Drug Class, By Type, By Route of Administration: Global Opportunity Analysis and Industry Forecast, 2021-2031 - Product Thumbnail Image

Psoriasis Therapeutics Market By Drug Class, By Type, By Route of Administration: Global Opportunity Analysis and Industry Forecast, 2021-2031

  • Report
  • September 2022
  • 242 Pages
  • Global
From
Inflammatory Bowel Disease Drugs Market By Type, By Drug Class, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031 - Product Thumbnail Image

Inflammatory Bowel Disease Drugs Market By Type, By Drug Class, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031

  • Report
  • July 2022
  • 274 Pages
  • Global
From
Graft Versus Host Disease Market By Product Type, By Treatment Type, By End Use: Global Opportunity Analysis and Industry Forecast, 2021-2031 - Product Thumbnail Image

Graft Versus Host Disease Market By Product Type, By Treatment Type, By End Use: Global Opportunity Analysis and Industry Forecast, 2021-2031

  • Report
  • June 2022
  • 230 Pages
  • Global
From
Loading Indicator

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications. The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more